Hideya Kamei1, Satohiro Masuda2, Taro Nakamura3, Masatoshi Ishigami4, Yasuhiro Fujimoto5, Yasuhiro Ogura5, Fumitaka Oike5, Yasutsugu Takada5, Nobuyuki Hamajima6. 1. Department of Transplantation Surgery, Nagoya University, 65 Tsurumai, Showa, Nagoya, 466-8550, Japan. kamei@med.nagoya-u.ac.jp. 2. Department of Pharmacy, Faculty of Medicine, Kyoto University, Kyoto, Japan. 3. Department of Transplantation Surgery, Nagoya University, 65 Tsurumai, Showa, Nagoya, 466-8550, Japan. 4. Department of Gastroenterology, Nagoya University, Nagoya, Japan. 5. Division of Hepato-Biliary-Pancreatic and Transplant Surgery, Department of Surgery, Kyoto University, Kyoto, Japan. 6. Department of Preventive Medicine, Nagoya University, Nagoya, Japan.
Abstract
PURPOSE: Despite improvements in immunosuppressive therapy, acute cellular rejection (ACR) remains an important cause of graft loss in patients undergoing liver transplantation. Recently, associations between cytokine gene polymorphisms in recipients and the occurrence of ACR have been reported. However, most studies did not investigate gene polymorphisms in donors or were limited by the number of cases investigated. METHODS: We examined 155 living donor liver transplantation (LDLT) patients treated at Nagoya University or Kyoto University from 2004 to 2009. The following gene polymorphisms in recipients and donors were analyzed: tumor necrosis factor A (TNF-A) T-1031C, interleukin 2 (IL-2) T-330G, IL-10C-819T, IL-13C-1111T, and transforming growth factor B (TGF-B) T29C. RESULTS: Forty-seven recipients (30.3 %) developed early ACR. Of the investigated gene polymorphisms, the IL-13 -1111C/C genotype in recipients was significantly associated with a higher incidence of ACR relative to the other two genotypes (OR = 2.64, 95 % CI 1.19-5.86, p = 0.017), while we showed the lack of association between investigated gene polymorphisms in donors and ACR incidence. CONCLUSION: The IL-13 -1111C/C genotype in recipients might be a risk factor for ACR in LDLT, and this might contribute to individualized immunosuppression strategies for recipients. On the other hand, the current study showed no associations of cytokine gene polymorphisms in donors with ACR incidence.
PURPOSE: Despite improvements in immunosuppressive therapy, acute cellular rejection (ACR) remains an important cause of graft loss in patients undergoing liver transplantation. Recently, associations between cytokine gene polymorphisms in recipients and the occurrence of ACR have been reported. However, most studies did not investigate gene polymorphisms in donors or were limited by the number of cases investigated. METHODS: We examined 155 living donor liver transplantation (LDLT) patients treated at Nagoya University or Kyoto University from 2004 to 2009. The following gene polymorphisms in recipients and donors were analyzed: tumor necrosis factor A (TNF-A) T-1031C, interleukin 2 (IL-2) T-330G, IL-10C-819T, IL-13C-1111T, and transforming growth factor B (TGF-B) T29C. RESULTS: Forty-seven recipients (30.3 %) developed early ACR. Of the investigated gene polymorphisms, the IL-13 -1111C/C genotype in recipients was significantly associated with a higher incidence of ACR relative to the other two genotypes (OR = 2.64, 95 % CI 1.19-5.86, p = 0.017), while we showed the lack of association between investigated gene polymorphisms in donors and ACR incidence. CONCLUSION: The IL-13 -1111C/C genotype in recipients might be a risk factor for ACR in LDLT, and this might contribute to individualized immunosuppression strategies for recipients. On the other hand, the current study showed no associations of cytokine gene polymorphisms in donors with ACR incidence.
Entities:
Keywords:
Gene polymorphisms; Graft rejection; Living donor liver transplantation
Authors: Steven C Hoffmann; Eran M Stanley; E Darrin Cox; Barbara S DiMercurio; Deloris E Koziol; David M Harlan; Allan D Kirk; Patrick J Blair Journal: Am J Transplant Date: 2002-07 Impact factor: 8.086
Authors: Saad F Jazrawi; Atif Zaman; Zafaruddin Muhammad; John M Rabkin; Christopher L Corless; Ali Olyaei; Amy Biggs; John Ham; Sunwen Chou; Hugo R Rosen Journal: Liver Transpl Date: 2003-04 Impact factor: 5.799
Authors: Sylvie Di Filippo; Adriana Zeevi; Kevin K McDade; Olivier Bastien; Steven A Webber Journal: Transplantation Date: 2006-03-27 Impact factor: 4.939
Authors: Daniel G Maluf; Richard Todd Stravitz; Adrian H Cotterell; Marc P Posner; Mitsuru Nakatsuka; Richard K Sterling; Velimir A Luketic; Mitchell L Shiffman; John M Ham; Amadeo Marcos; Martha K Behnke; Robert A Fisher Journal: Am J Transplant Date: 2005-01 Impact factor: 8.086
Authors: M C Warlé; A Farhan; H J Metselaar; W C Hop; A J van der Plas; M Kap; S de Rave; J Kwekkeboom; P E Zondervan; J N IJzermans; H W Tilanus; V Pravica; I V Hutchinson; G J Bouma Journal: Hum Immunol Date: 2001-11 Impact factor: 2.850
Authors: T D Howard; P A Whittaker; A L Zaiman; G H Koppelman; J Xu; M T Hanley; D A Meyers; D S Postma; E R Bleecker Journal: Am J Respir Cell Mol Biol Date: 2001-09 Impact factor: 6.914